Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06293820 · ClinicalTrials.gov registry record · Phase 2
A Study Of TL-925 For The Treatment of AC
A Phase 2 study, sponsored by Telios Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT06293820 is a Phase 2 study that has completed, run by Telios Pharma. The registered enrollment target is 80 participants.
The verdict
NCT06293820, a Phase 2 study, has completed, sponsored by Telios Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Interventions
- DRUG Placebo
- DRUG TL-925
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-04-11 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06293820
The ClinicalTrials.gov registry entry for NCT06293820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Telios Pharma, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06293820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06293820 about?
NCT06293820 is a clinical study titled "A Study Of TL-925 For The Treatment of AC". In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using th...
What is the current status of trial NCT06293820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2024-04-11. Estimated completion is 2024-05-21.
What interventions are being tested in trial NCT06293820?
The interventions under investigation include: Placebo (DRUG), TL-925 (DRUG).
Who is sponsoring clinical trial NCT06293820?
This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.